Patent ID: 9217001
Filing Date: 2015-12-22
Classification: A61P,C07B,C07D,C07F

Abstract:
1. A process for preparing Bortezomib (Ia) crystalline Form-SB characterized by X-ray powder diffraction pattern comprising the characteristic 2θ° peaks of 5.6, 7.5, 9.8, 10.2, 11.3, 15.1, 18.0, 20.5, 21.5 and 23.6±0.20 2θ°, wherein peaks at 9.8 and 11.39±0.20 2θ° are un-split and 100% intensity peak is present at 5.6+0.20 2θ°, DSC isotherm comprising the endothermic peaks ranging between 45 to 60° C. (Peak-1) and 175 to 185° C. (Peak-2) and IR absorption characteristic peaks approximately at 3387 cm a) combining the Bortezomib with an aliphatic ester solvent or a mixture of aliphatic ester solvent and water; b) raise the temperature up to about 40-70° C.; c) stir the solution at same temperature up to a time between 15 to 60 minutes; d) combine with aliphatic C6 to C7 hydrocarbon solvent; e) optionally maintain the mixture for 10-60 minutes; f) cooling the mixture up to about 10-40° C.; and g) isolating the crystalline material.